Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), an immunotherapy company specializing in engineered T cell therapeutics, has announced a series of strategic moves aimed at ...

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

China Emerging Key Player in Development Of Gamma Delta T Cell Cancer Therapy Says KUICK RESEARCHDelhi, Jan. 29, 2025 (GLOBE ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

In a groundbreaking study, researchers from Columbia Engineering and the Irving Institute for Cancer Dynamics have identified a unique population of immune cells crucial for effective immunotherapy ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in cancer immunotherapy. The Tribune, now published from Chandigarh ...